These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24433595)

  • 1. Sublingual immunotherapy for aeroallergens: status in the United States.
    Cox L
    Allergy Asthma Proc; 2014; 35(1):34-42. PubMed ID: 24433595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy.
    Larenas-Linnemann DE; Mösges R
    Allergy Asthma Proc; 2016; 37(1):50-6. PubMed ID: 26831847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Evidence on Safety and Practical Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United States.
    Epstein TG; Calabria C; Cox LS; Dreborg S
    J Allergy Clin Immunol Pract; 2017; 5(1):34-40.e2. PubMed ID: 27815065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA.
    Nelson HS
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1437-51. PubMed ID: 25340426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of patients for sublingual versus subcutaneous immunotherapy.
    Larenas Linnemann DE; Blaiss MS
    Immunotherapy; 2014; 6(7):871-84. PubMed ID: 25290418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual immunotherapy: the U.S. experience.
    Nelson HS
    Curr Opin Allergy Clin Immunol; 2013 Dec; 13(6):663-8. PubMed ID: 24169432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units.
    Larenas-Linnemann D; Esch R; Plunkett G; Brown S; Maddox D; Barnes C; Constable D
    Ann Allergy Asthma Immunol; 2011 Nov; 107(5):448-458.e3. PubMed ID: 22018618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual Immunotherapy for the Polyallergic Patient.
    Pepper AN; Calderón MA; Casale TB
    J Allergy Clin Immunol Pract; 2017; 5(1):41-45. PubMed ID: 27452888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
    Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
    Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
    J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective?
    Nelson HS
    J Allergy Clin Immunol Pract; 2014; 2(2):144-9; quiz 150-1. PubMed ID: 24607040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual immunotherapy: current concepts for the U.S. practitioner.
    Lin SY
    Int Forum Allergy Rhinol; 2014 Sep; 4 Suppl 2():S55-9. PubMed ID: 25182357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
    Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
    Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
    Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
    J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical aspects of sublingual immunotherapy tablets and drops.
    Tankersley M; Han JK; Nolte H
    Ann Allergy Asthma Immunol; 2020 Jun; 124(6):573-582. PubMed ID: 31923544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual or subcutaneous immunotherapy for allergic rhinitis?
    Durham SR; Penagos M
    J Allergy Clin Immunol; 2016 Feb; 137(2):339-349.e10. PubMed ID: 26853126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
    Esch RE; Bush RK; Peden D; Lockey RF
    Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublingual grass and ragweed immunotherapy: Clinical considerations-a PRACTALL consensus report.
    Li JT; Bernstein DI; Calderon MA; Casale TB; Cox L; Passalacqua G; Pfaar O; Papadopoulos NG
    J Allergy Clin Immunol; 2016 Feb; 137(2):369-76. PubMed ID: 26371843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy.
    Nelson H; Cartier S; Allen-Ramey F; Lawton S; Calderon MA
    J Allergy Clin Immunol Pract; 2015; 3(2):256-266.e3. PubMed ID: 25609326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.